At-Home Infusion Using Bamlanivimab in Participants With Mild to Moderate COVID-19
Status:
Completed
Trial end date:
2021-04-18
Target enrollment:
Participant gender:
Summary
This is an open-label, pragmatic, single-dose study using matched controls in participants
with mild to moderate COVID-19. Participants will track for developing symptoms while at home
and upon reporting of symptoms will test for COVID-19. If positive for COVID-19, a one-time
at-home infusion of Bamlanivimab (LY3819253) will be provided by Optum Infusion. Participants
will then track for 28 days to assess for any additional medical care needed or if
hospitalization was required.